Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15.

Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D.

Abstract
Bendamustine, active in multiple myeloma (MM), is a bifunctional mechlorethamine derivative with alkylating properties. Bortezomib, approved to treat MM, is effective in combination with alkylators. The tolerability and efficacy of bendamustine plus bortezomib in relapsed/refractory MM was assessed in an open-label, dose-escalating, phase I/II study. Patients aged ≥18 years received intravenous bendamustine 50, 70, or 90 mg/m(2) (days 1 and 4) plus bortezomib 1·0 mg/m(2) (days 1, 4, 8, and 11) for up to eight 28-day cycles. No dose-limiting toxicity was observed after cycle 1; bendamustine 90 mg/m(2) plus bortezomib 1·0 mg/m(2) was designated the maximum tolerated dose (MTD). The most common grade 3/4 adverse events were leucopenia (58%), neutropenia (50%), lymphopenia (45%), and thrombocytopenia (30%). Primary efficacy measure was overall response rate (ORR), which was the combined complete response (CR), very good partial response (VGPR), partial response (PR), and minimal response (MR). ORR was 48% (one CR, two VGPR, nine PR, and seven MR) for all 40 enrolled patients, 52% (16/31) at the MTD (90 mg/m(2) ), and 42% and 46% for prior use of bortezomib (n = 31) or alkylators (n = 28) respectively. Bendamustine plus bortezomib was well tolerated with promising efficacy in this heavily pretreated population.

Download Paper

Make an Appointment

Related Articles

[dgbm_blog_module posts_number=”3″ show_thumbnail=”off” show_author=”off” show_pagination=”off” show_more=”on” space_between=”42px” equal_height=”on” container_margin=”||||false|false” container_padding=”||||false|false” article_margin=”||||false|false” article_padding=”||||false|false” content_margin=”||||false|false” content_padding=”30px|30px|30px|30px|true|true” meta_bottom_padding=”||||false|false” button_wrapper_margin=”20px||||false|false” category_location=”top” date_margin=”10px||10px||true|false” module_class=”zdm-blog-grid” _builder_version=”4.21.0″ _module_preset=”default” title_text_color=”#17374E” title_line_height=”1.1em” read_more_font=”||||||||” read_more_text_color=”#009ACA” read_more_font_size=”16px” date_font=”|600|||||||” date_text_color=”#2C6893″ date_font_size=”13px” category_font=”|600||on|||||” category_text_color=”#2C6893″ category_font_size=”13px” category_letter_spacing=”1px” background_color=”#FFFFFF” border_width_all_post_item=”2px” border_color_all_post_item=”gcid-f0845e9b-066a-4b8b-a6b5-20f5259bbdfd” border_style_all_post_item=”dashed” global_colors_info=”{%22gcid-f0845e9b-066a-4b8b-a6b5-20f5259bbdfd%22:%91%22border_color_all_post_item%22%93}” read_more_text_color__hover_enabled=”on|desktop” read_more_text_color__hover=”#16B591″ title_text_color__hover_enabled=”on|desktop” title_text_color__hover=”#2C6893″ category_text_color__hover_enabled=”on|desktop” category_text_color__hover=”#2C6893″][/dgbm_blog_module]